Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR439459 in adults with Osteogenesis Imperfecta
NCT05231668Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing SAR439459 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs) at 24 weeks. Started Aug 2022; status: terminated.
02
Drugs
SAR439459
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT05231668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231668.